MGC Pharmaceuticals secures European approval for derma products

The registration with the European Cosmetics Products Notification Portal (CPNP) follows the successful completion of safety assessment, which included skin patch tests on 30 human volunteers.

The development of a dermatologically tested cannabidiol skin care product range is a key priority for MGC, given the significant commercial opportunity that such products represents globally.

The company is moving to clinical tests on human volunteers in January 2017 that will take place at a Slovenian dermatology clinic to determine the efficacy of its product range.

This is a three-month clinical trial on human volunteers across its 3 cannabidiol based dermatological products to investigate their efficacy for the symptoms of psoriasis, acne and seborrhoea conditions.

The development of a dermatological skin care products range complements the company’s existing cannabidiol based cosmetics product range, under its recently rebranded MGC Derma brand.

Last month, the company signed a distribution agreement for cosmetics products worth $500,000 in gross sales per annum

... read more at: http://www.proactiveinvestors.com.au/companies/news/171294/mgc-pharmaceuticals-secures-european-approval-for-derma-products

by